Navigation Links
XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
Date:10/22/2007

sign that consists of multiple 6mm cobalt chromium segments coated with Biolimus A9(R) and PLA, a biodegradable drug carrier. The Custom NX delivery system enables separation at each 6mm segment and allows for the placement of up to 60mm of stent.

CUSTOM I and II Webcast and Slide Presentation

As previously announced, XTENT will host a teleconference and slide presentation to review the CUSTOM I and CUSTOM II data at 7:00 a.m. EDT on Monday, October 22. The public can access the webcast via the investor relations section of the company's website at http://investor.xtentinc.com/events.cfm, or by calling 888-663-2258 (from the U.S.), 913-312-1277 (international). Please dial in or access the Web site five to ten minutes prior to the beginning of the call. The webcast will be archived on the Web site for a minimum of three months, and can be accessed at the investor relations portion of the company's Web site at http://investor.xtentinc.com.

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may
'/>"/>

SOURCE XTENT, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. XTENT Announces Promising Six-Month Custom II Trial Data Presented at EuroPCR Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Report Details  New ... companies  What does the future hold for ... Visiongain,s brand new report shows you potential revenues to ... Our 242-page report provides 185 tables, charts, and ... and the future market prospects. Our new study lets ...
(Date:3/27/2015)... 2015 The International Myeloma Foundation (IMF) – ... working toward prevention and a cure – today commended ... federal resolution (H. Res. 174) that supports the designation ... Myeloma Awareness Month." Currently there are more ... than 110,000 new cases are diagnosed yearly, according to ...
(Date:3/27/2015)... 27, 2015 RnRMarketResearch.com adds ... market research report of 52 pages with latest ... intelligence library. The report "Visceral Pain - Pipeline ... therapeutic development for Visceral Pain, complete with comparative ... target, mechanism of action (MoA), route of administration ...
Breaking Medicine Technology:Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4
... MEETING, Pa., Feb. 10 Genaera Corporation (Nasdaq: ... clinical data for trodusquemine (MSI-1436), the first-in-class, highly selective ... the treatment of type 2 diabetes and obesity. ... data from the first of three cohorts in an ...
... A new study published today claiming that multivitamin ... risk of mortality fails to take into account important ... health claims are regulated by the U.S. Food and ... published in the February 9 issue of Archives ...
Cached Medicine Technology:Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436) 2Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436) 3Evidence Lacking in Multivitamin Study of Women's Risk of Cancer, Heart Disease or Death, Says Natural Products Association 2
(Date:3/27/2015)... First Choice Emergency Room opened ... is located 12665 W Lake Houston Pkwy, Houston, Texas and ... I look forward to delivering the highest quality emergency medical ... Director of First Choice Emergency Room Summerwood. , ... donation to Summer Creek High School at First Choice Emergency ...
(Date:3/27/2015)... March 27, 2015 Healthpointe is proud ... Katz, M.D., is now treating knee and hip joint ... Anaheim , Long Beach, and La Mirada. Dr. Stanley ... knee and hip joint disorders as well as chronic ... passionate in returning his patients back to their normal ...
(Date:3/27/2015)... The report “CountryFocus Healthcare, Regulatory ... source of information on and analysis of the ... increasingly elderly population and its associated disease burden ... 2013, the elderly accounted for 27.1% of the ... Growth Rate (CAGR) of 1.2% to 29.5% in ...
(Date:3/27/2015)... According to a recently published report series by ... market in Europe is in decline due to decreasing ... Price decreases are being seen across the entire orthopedic ... total European trauma device market, continued pricing pressure overall ... after year. , “Such price drops are typical ...
(Date:3/27/2015)... March 27, 2015 Endure Yoga is ... functional fitness athletes. This new program matches yoga poses ... for post-workout cool down. This program utilizes yoga to ... and mental focus. , Karen Lefurgy, competitive athlete ... yoga long before I started Crossfit® training, but quickly, ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Opens New Facility in Houston, Texas 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 2Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 4Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 3Health News:Endure Yoga Introduces WOD Recovery Yoga 2
... You might call this a professional car wash salon with a personal ... lady at the wheel, going swish swash, spraying water on your car ... give the lady (your car) a kick, then you could choose a ... ,Professional car wash centers are thriving in Brisbane as residents ...
... and research at the Baltimore institution Johns Hopkins officials ... Medicine from His Highness Sheikh Khalifa bin Zayed ... (UAE). Most of the gift, made in honor of ... Nahyan, will support construction of The Johns Hopkins Hospitals ...
... asthma has been clearly described, but a new study ... (HSPH) finds a strong association between domestic violence and ... of the International Journal of Epidemiology, raises questions about ... common respiratory condition. ,"Classic environmental triggers ...
... determine the true effects of low to moderate alcohol ... pregnant women of different policies on alcohol consumption ... ,Recommendations for safe levels of drinking during pregnancy vary ... Australia, according to new report written by Colleen OLeary ...
... of the river Yamuna is a major problem. ... was possible some years ago," Indian Space Research Organisation ... Dayalbagh University here. ,"The prevailing conditions make ... wonder why people are not alarmed and concerned about the ...
... medical community has repeatedly warned against plying young children with ... seem to care . Certainly not in Australia. ,Many ... dentists in that country say. ,In the most ... to remove all 20 baby teeth. ,"It's a ...
Cached Medicine News:Health News:Johns Hopkins Medicine Honors U.A.E. Sheikh Zayed Bin Sultan Al Nahyan 2Health News:Johns Hopkins Medicine Honors U.A.E. Sheikh Zayed Bin Sultan Al Nahyan 3Health News:Research Demonstrates Link Between Domestic Violence and Asthma 2Health News:Better Research Needed On Alcohol In Pregnancy 2Health News:Experts Call for Warning Lables on Fruit Juice to Save Kids' Teeth 2
... (IGF-I or somatomedin C) is a 7.6 kDa ... as a potent mitogen of cellular proliferation, exerting ... In the circulation, IGF-I is bound to IGF-binding ... of IGF-I by modulating the interaction of IGF-I ...
... name from its first known site of ... of PSA circulates bound to anti-chymotrypsin (PSA-ACT) ... PSA are elevated in patients with prostate ... [1-3]. In addition, PSA serum levels appear ...
Inquire...
The design of this table top is based on advanced functionality for specific urological requirements. This composite product sets a new standard for urological imaging....
Medicine Products: